Argenx Se ARGX
NASDAQ ARGX
$1,033.15 -20.31 (-1.93%)
At close: Sep 4, 2026 · 4:00 PM EDT

Argenx Se (ARGX) Other Non-Current Assets (2016 - 2026)

Argenx Se's (ARGX) quarterly Other Non-Current Assets came in at $124.0 million in Q2 2026, down 99.73% on a YoY basis from $46.7 billion in Q2 2025, and up 125.45% quarter-over-quarter from $55.0 million in Q4 2025.

Analysis

Argenx Se (ARGX) Other Non-Current Assets (2016 - 2026) Analysis & Trends

Argenx Se (ARGX) has reported Other Non-Current Assets for 11 consecutive years, with $124.0 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Other Non-Current Assets fell 99.73% year-over-year to $124.0 million; the trailing twelve-month figure through Jun 2026 stood at $124.0 million (down 99.73% YoY), and the FY2025 full-year result was $55.0 million, down 99.87% from the prior year.
  • Other Non-Current Assets improved to $124.0 million in Q2 2026 per ARGX's latest filing, from $55.0 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $46.7 billion in Q2 2025 and bottomed at $34.3 million in Q2 2024.
  • Historically, Other Non-Current Assets has averaged $14.5 billion across 5 years, with a median of $55.0 million in 2025.
  • The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets slumped 99.9% in 2023, then soared 136097.34% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $40.9 billion in 2022, then plunged by 99.9% to $39.7 million in 2023, then soared by 106785.68% to $42.4 billion in 2024, then sank by 99.87% to $55.0 million in 2025, then jumped by 125.45% to $124.0 million in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods registered $124.0 million, $55.0 million, and $46.7 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 12.98 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 4.75 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 1.25 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 2.31 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn 124.00 Mn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn 618.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 65.13 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 831.80 Mn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn 104.44 Mn
10 BioNTech SE 26.24 Bn 12.58 Bn 10.00 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 124.00 Mn
Dec 31, 2025 55.00 Mn
Jun 30, 2025 46.68 Bn
Dec 31, 2024 42.39 Bn
Jun 30, 2024 34.28 Mn
Dec 31, 2023 39.66 Mn
Jun 30, 2023 39.23 Mn
Dec 31, 2022 40.89 Bn
Jun 30, 2022 43.10 Mn
Dec 31, 2021 54.88 Bn
Jun 30, 2021 1.44 Mn
Dec 31, 2020 7.61 Bn
Jun 30, 2020 696,122.80
Dec 31, 2019 3.57 Bn
Jun 30, 2019 400,015.52
Dec 31, 2018 287,631.90
Jun 30, 2018 313,875.88
Dec 31, 2017 147,179.07
Jun 30, 2017 1.86 Mn
Dec 31, 2016 1.24 Mn